CompletedNCT00683462
AZD3480 or placebo for adult ADHD
About this title
Read the official source — NCT00683462Researchers compared AZD3480 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared AZD3480 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- BurlingtonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00683462
- Official title
Show the full official title
An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBurlington
Questions about this study
What did researchers investigate?
Researchers compared AZD3480 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Placebo and AZD3480.
Who was this study for?
Listed age limits: 18 years to 65 years.
